Disclaimer: The following video is a paid advertisement and viewers are not to consider the contents as an endorsement of products or services by the ANA. The materials, information or opinions provided during the videos are solely those of the individuals and companies involved and do not necessarily represent those of the ANA.
ANA Spotlights: New Hope for Early-Stage Alzheimer's Disease: Can We Modify the Disease Pathway by Targeting Amyloid-β?
Sponsored By: Answers in CME (This activity is supported by an educational grant from Biogen)
Date/Time: Held Live on Tuesday, October 19, 2021 - 8:30 AM – 9:30 AM
The objective of this activity series is to improve neurologists’ knowledge and competence in evaluating the rationale behind selectively targeting neurotoxic soluble amyloid-β oligomers in early-stage AD, assessing the latest evidence on the efficacy and safety of emerging late-stage anti-amyloid-β immunotherapies and proposing a patient-centered approach that will maximize the benefits of these emerging therapies.
- Marwan N. Sabbagh, MD; Cleveland Clinic
- James E. Galvin, MD, MPH; University of Miami Miller School of Medicine
- Lueva Demps; Alzheimer's Caregiver